Daily Ischemic Preconditioning Provides Sustained Protection From Ischemia–Reperfusion Induced Endothelial Dysfunction: A Human Study

Mary Clare Luca, PhD; Andrew Liuni, PhD; Kelsey McLaughlin, BSc; Tommaso Gori, MD, PhD; John D. Parker, MD

Background—It is well established that acute ischemic preconditioning (IPC) protects against ischemia–reperfusion (IR) injury; however, the effectiveness of repeated IPC exposure has not been extensively investigated. We aimed to determine whether daily IPC episodes provide continued protection from IR injury in a human forearm model, and the role of cyclooxygenase-2 in these responses.

Methods and Results—Thirty healthy volunteers were randomized to participate in 2 of 3 protocols (IR alone, 1-day IPC, 7-day IPC) in an operator-blinded, crossover design. Subjects in the IR alone protocol underwent flow-mediated dilation (FMD) measurements pre- and post-IR (15' upper-arm ischemia and 15' reperfusion). The 1-day IPC protocol involved FMD measurements before and after 1 episode of IPC (3 cycles of 5’ upper-arm ischemia and 5’ reperfusion) and IR. Day 7 of the 7-day IPC protocol was identical to the 1-day IPC protocol but was preceded by single daily episodes of IPC for 6 days prior. During each protocol, subjects received a 7-day treatment of either the cyclooxygenase-2 inhibitor celecoxib or placebo. Pre-IR FMD was similar between groups. IR alone reduced FMD post-IR (placebo, ΔFMD: −4.4±0.7%; celecoxib, ΔFMD: −5.0±0.5%). One-day IPC completely prevented this effect (placebo, ΔFMD: −1.1±0.6%; celecoxib, ΔFMD: 0.0±0.7%; P<0.0001). Similarly, 7-day IPC demonstrated persistent endothelial protection post-IR (placebo, ΔFMD: −0.9±0.9%; celecoxib, ΔFMD: 0.0±0.8%; P<0.0001, P<0.0001 for ANOVA effect of IPC protocol). Celecoxib did not alter responses to IR in any protocol.

Conclusions—Daily episodes of IPC provide sustained protection from IR-induced endothelial dysfunction in humans through a mechanism that appears cyclooxygenase-2-independent. (J Am Heart Assoc. 2013;2:e000075 doi: 10.1161/JAHA.112.000075)

Key Words: cyclooxygenase-2 • endothelium • ischemia • ischemic preconditioning • reperfusion

Restoration of blood flow after severe ischemia or ongoing infarction results in further tissue damage, a phenomenon known as ischemia–reperfusion (IR) injury. IR injury has been shown to cause arrhythmias, vascular endothelial dysfunction, myocardial stunning, and cell death.1 Endothelial cells are particularly sensitive to, and actively participate in the progression of IR injury. They are the first cellular population to experience reperfusion and have a major impact on subsequent blood flow responses to areas of prior ischemia.2,3 A state of endothelial dysfunction commonly occurs following IR injury, which can impair tissue perfusion through the activation of neutrophils and platelets and exacerbate tissue damage.4 The endothelium’s sensitivity to IR injury has been demonstrated in several experiments where exposure to short periods of IR caused selective endothelial dysfunction while leaving vascular smooth muscle function unimpaired,2,4 although this has not been consistently demonstrated.5 Furthermore, it has been shown that the kinetics of cell death during IR are cell-specific with endothelial cells succumbing prior to cardiomyocytes.6 Thus, the endothelium is extremely sensitive to IR injury, but at the same time is a major determinant of the tissue’s ability to recover from IR. Therefore, studies aimed at protecting the endothelium from IR, particularly when conducted in humans, should be considered of direct clinical interest.

It has been demonstrated that exposure to brief periods of ischemia (termed ischemic preconditioning [IPC]) before a prolonged ischemic insult can reduce myocardial and endothelial sensitivity to IR-induced injury,4,7 a phenomenon that has been observed in every species tested, including humans.8 The potent protective effects of preconditioning

From the Division of Cardiology, Mount Sinai and University Health Network Hospitals, Toronto, Canada (M.L., A.L., K.M., J.D.P.); Department of Pharmacology and Toxicology, University of Toronto, Canada (M.L., A.L., K.M., J.D.P.); and Medizinische Klinik, University Medical Center Mainz, Germany (T.G.).

Correspondence to: John D. Parker, MD, Professor of Medicine and Pharmacology, University of Toronto, Division of Cardiology, Mount Sinai and University Health Network Hospitals, 600 University Avenue, Suite 1609, Toronto, Canada, MSG 1X5. E-mail: john.parker@uhn.ca

Received September 27, 2012; accepted January 17, 2013.

© 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley-Blackwell. This is an Open Access article under the terms of the Creative Commons Attribution Noncommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
provide attractive opportunities for therapeutic intervention. For example, preconditioning may have clinical applications in the setting of programmed ischemia (eg, during percutaneous coronary angioplasty\(^9\) or coronary artery bypass surgery\(^10\)). Although preconditioning interventions have been used to improve mortality and morbidity in patients experiencing spontaneous myocardial infarction,\(^11\) this therapeutic approach remains largely unexploited in clinical practice. An important, intrinsic limitation is that spontaneous, acute myocardial infarction therapeutic preconditioning can only be applied after the onset of infarction, an approach that limits their effectiveness as compared to animal models of “planned” myocardial infarction. One approach to this problem, which might find application in patients at high risk of myocardial infarction, would be the development of repeated preconditioning treatment algorithms that would provide ongoing protection from the effects of IR. To date, this approach has not been explored in humans. Therefore, the purpose of the current investigation was to determine whether the protective effects of IPC are maintained when administered repeatedly over time.

**Methods**

**Population**

Thirty young, healthy, male volunteers (20 to 31 years old) were enrolled to participate in this operator-blinded, placebo-controlled, crossover design study. The Mount Sinai Research Ethics Board approved the protocols and all subjects gave informed consent prior to beginning the study. Exclusion criteria included any active disease, the use of medications (including supplemental vitamins), as well as risk factors for cardiovascular disease such as hypertension, smoking, or hypercholesterolemia.

**Study Protocols**

This study involved 3 separate protocols, which were designed to study the effect of (1) IR alone on flow-mediated dilation (FMD) (with no IPC); (2) the effect of IR on FMD after a single episode of IPC and, finally (3) the effect of IR on FMD after 7 days of repeated episodes of IPC. Each protocol included 20 volunteers randomized (in a double-blind fashion) to either celecoxib 200 mg bid or matching placebo bid. Each participant participated in 2 of the 3 protocols (Figure 1).

**Study Methodology**

Studies were conducted in a quiet, temperature- and humidity-controlled environment. All subjects were required to fast and abstain from caffeine for 24 hours prior to the study. After admission to the study, subjects were randomized in a double-blind fashion to celecoxib 200 mg bid or placebo. They were subsequently randomized to participate in 2 of 3 protocols (IR alone, 1-day IPC, 7-day IPC; described below) in a crossover fashion (with a minimum 7 days of washout between each protocol). A research nurse not involved in acquisition or analysis of study data performed all randomization and maintained appropriate logs. The first author performed the preconditioning protocols including data acquisition and measurement. Upon completion of the study, data files were coded and all FMD analyses were performed in a blinded fashion.

**IR Alone Protocol**

Initially, subjects were randomized to 200 mg bid of celecoxib or matching placebo for the 7 days prior to, and including the day of the study visit. On the day of the study visit, standing blood pressure measurements were obtained after 10 minutes of rest, using an automatic, calibrated sphygmomanometer (GE Healthcare). Radial artery FMD was then measured as previously described.\(^12\)–\(^14\) Subsequently, subjects underwent an episode of forearm IR by placing a pneumatic cuff at the level of the brachial artery and inflating it to 250 mm Hg.
for 15 minutes, followed by 15 minutes of reperfusion. FMD measurements were repeated immediately following the period of IR (Figure 1A). This model, which causes a marked impairment in endothelium-dependent vasodilation while leaving endothelium-independent vasodilation intact, has been recently employed in multiple studies of IR injury and preconditioning (including a number from our group). The repeatability and reproducibility of FMD as assessed in our laboratory have been described previously.

1-Day Protocol

The 1-day protocol consisted of subjects being administered 200 mg bid of celecoxib or matching placebo for the 7 days prior to and including the day of the study visit. On the day of the study visit, subjects underwent a baseline assessment of FMD followed by a single episode of IPC (3 cycles of 5′ upper arm ischemia followed by 5′ reperfusion). Subsequently, subjects underwent the 15′ ischemia and, after 15′ of reperfusion, a second assessment of FMD (Figure 1B).

7-Day Protocol

The 7-day protocol consisted of subjects visiting the laboratory 6 consecutive times, each 24 hours apart, during which they underwent a single episode of IPC as described above. On day 1, subjects began a 7-day regimen of 200 mg bid of celecoxib or matching placebo. Twenty-four hours after the end of the sixth IPC visit, the seventh visit consisted of measuring radial artery FMD before and after episodes of IPC and IR as in the 1-day protocol (Figure 1C).

Statistical Analysis

Sample size estimates for this study assume $1-\beta=0.8$ and a 2-sided $\alpha$ of 0.05. For this study, sample size estimates were made based on previous data from our laboratory. IR decreased FMD responses from 7.9±3.3% to 1.2±2.3%. Prevention of 50% of this impairment via IPC-induced preconditioning requires a sample size of 10 subjects in each crossover group. A 2-way analysis of variance was carried with the different IPC protocols (ie, IR alone, 1-day IPC, or 7-day IPC) and drug (placebo or celecoxib) as between-subject factors (IPC protocol and drug, respectively). This analysis was used to assess the effects of both IPC and drug allocation on the change in FMD after IR ($\Delta$FMD) in the 3 protocols. Post hoc comparisons were performed using the Bonferroni correction. A value of $P<0.05$ was set as the threshold for significance. All results are presented as mean±SE. SAS 9.1.3 (SAS Institute, Inc.) was used for all statistical analyses.

Results

Radial artery diameter, the change in radial artery diameter in response to reactive hyperemia (ie, during FMD), and blood flow data are presented in the Table. $\Delta$FMD data are presented in Figure 2.

Baseline Parameters

There were no significant differences in radial artery diameter, baseline blood flow, reactive hyperemia or change in arterial diameter following wrist cuff deflation between protocols in those who were treated with placebo or celecoxib (Table 1). Hemodynamic parameters (systolic blood pressure, diastolic blood pressure, and mean arterial pressure) were not significantly different between any of the groups.

Effect of IR

There were no significant differences in either baseline diameter or baseline blood flow before versus after IR in any protocol ($P$=NS for all; Table), nor were there any differences in peak reactive hyperemia before versus after IR in any of the protocols (Table). In both the placebo and celecoxib groups, IR alone reduced FMD (Figure 2; placebo, $\Delta$FMD: $-4.4\pm0.7$%; celecoxib, $\Delta$FMD: $-5.0\pm0.5$%), whereas the adverse effect of IR on FMD with IR was significantly reduced in both the 1-day IPC (Figure 2; placebo, $\Delta$FMD: $-1.1\pm0.6$%; celecoxib, $\Delta$FMD: $0.0\pm0.7$%; $P<0.0001$) and 7-day IPC protocols (Figure 2; placebo, $\Delta$FMD: $-0.9\pm0.9$%; celecoxib, $\Delta$FMD: $0.0\pm0.8$%; $P<0.0001$). The ANOVA revealed a significant effect of IPC protocol on $\Delta$FMD ($P<0.0001$). There was no difference in the protective effect of IPC between the 1-day and 7-day IPC protocols.

Effect of Celecoxib

In each of the protocols (IR alone, 1-day IPC, 7-day IPC), there were no significant differences between the placebo and celecoxib cohorts with regards to baseline parameters (ie, hemodynamic parameters, or baseline diameter, baseline blood flow, reactive hyperemia, and FMD before IR), nor were there any differences in the FMD responses with IR ($P$=NS for all; Table and Figure 2).

Discussion

Since the initial observation that brief, sublethal episodes of myocardial ischemia provide remarkable protection in the setting of myocardial function, the phenomenon of IPC has been shown to be reproducible and effective in multiple
Endothelial Protection with Daily Preconditioning  Luca et al

DOI: 10.1161/JAHA.112.000075

Table. Arterial Diameter and Blood Flow Data

| Radial Artery Diameter, mm | Before IR | After IR | Absolute Change in Diameter | Baseline Diameter | After Wrist Cuff Deflation | Absolute Change in Diameter | Baseline Diameter | After Wrist Cuff Deflation |
|---------------------------|-----------|----------|-----------------------------|-------------------|---------------------------|-----------------------------|-------------------|---------------------------|
| Placebo                   | IR alone  | 2.23±0.13| 0.17±0.01                   | 2.21±0.13         | 0.07±0.01*                | 1-day IPC                  | 2.42±0.09         | 0.16±0.01                   | 2.40±0.10         | 0.13±0.02                |
|                           | 7-day IPC | 2.41±0.12| 0.19±0.02                   | 2.42±0.13         | 0.20±0.02                |
| Celecoxib                 | IR alone  | 2.26±0.12| 0.17±0.02                   | 2.24±0.12         | 0.06±0.01**               | 1-day IPC                  | 2.34±0.09         | 0.16±0.02                   | 2.26±0.08         | 0.15±0.02                |
|                           | 7-day IPC | 2.27±0.10| 0.16±0.02                   | 2.25±0.10         | 0.16±0.02                |
| Blood Flow, mL/min        | Before IR |          | After Wrist Cuff Deflation  | Reactive Hyperemia, % | Baseline Diameter | After Wrist Cuff Deflation | Reactive Hyperemia, % |
| Placebo                   | IR alone  | 12.4±4.3 | 87.3±15.0                   | 1080±203          | 8.7±1.9                  | 1-day IPC                  | 15.3±3.6         | 119.5±12.9                 | 1003±228          | 12.3±2.0                 | 109.4±10.3         | 937±146                |
|                           | 7-day IPC | 13.4±3.4 | 103.7±14.3                 | 941±158           | 11.0±3.8                 | 101.6±15.4                 | 1094±224         |
| Celecoxib                 | IR alone  | 11.0±2.2 | 89.3±10.8                  | 879±152           | 11.4±3.1                 | 1-day IPC                  | 13.4±1.7         | 110.7±13.1                 | 793±127           | 10.7±2.8                 | 102.8±11.9         | 1340±432              |
|                           | 7-day IPC | 13.0±4.1 | 110.0±19.5                 | 912±203           | 11.5±4.7                 | 101.0±17.3                 | 1064±230         |

Radial artery diameter and blood flow at baseline and during reactive hyperemia are presented. n=10 per group. IR indicates ischemia–reperfusion; IPC, ischemic preconditioning.

*P<0.001; **P<0.001: both for absolute change from baseline compared to before IR.

organs and species. IPC has generated tremendous scientific interest being described as the most powerful available form of in vivo protection against myocardial ischemic injury. However, despite over 20 years of research, preconditioning strategies have not yet been widely implemented in clinical practice. Most efforts in the development of therapeutic cardiovascular preconditioning have been designed to limit damage in the setting of acute myocardial infarction. In this case, preconditioning (or “perconditioning”) stimuli are used in an effort to limit damage after the onset of the infarction process. Preconditioning interventions have also been used in an effort to limit damage during procedures where IR injury predictably occurs (such as during percutaneous interventions and cardiopulmonary bypass). Theoretically, the phenomena of preconditioning could also be used in patients to limit symptoms (eg, exertional angina) or to provide ongoing protection from the consequences of acute ischemia or infarction. The ability to exploit this potential clinical application of preconditioning (either ischemic or pharmacologic) is dependent on whether a “preconditioned state” can be maintained over time. With these considerations in mind, the development of preconditioning techniques that do not result in tachyphylaxis or tolerance when administered in a repetitive fashion is an important therapeutic goal. A number of studies have examined the ability of repeated pharmacologic stimuli to induce a sustained preconditioning phenotype. Exposure to HMG-CoA reductase inhibitors, opioid agonists, chronic adenosine receptor activation, and nitroglycerin have been mixed, with some experiments demonstrating sustained protection with others showing loss of protection over time. Although a single exposure to nitroglycerin has repeatedly been shown to have protective cardiovascular effects in humans, we recently reported that repeated, daily 2-hour exposure to nitroglycerin was associated with loss of its preconditioning effects. HMG-CoA reductase inhibitors have also been explored as preconditioning agents in models of human disease. A number of studies have documented that HMG-CoA reductase inhibitors are protective in the setting of angioplasty, myocardial infarction, and cardiac surgery. Although these studies made use of sustained dosing regimens, the positive treatment effect was driven mostly by an impact on periprocedural events and the independent impact of “chronic dosing” was not clearly defined. Our group has recently completed a study in which the effects of 3 weeks of daily therapy with rosuvastatin on the response to IR were compared to those observed in
Endothelial Protection with Daily Preconditioning

Luca et al

mediated dilation; IPC, ischemic preconditioning.

DOI: 10.1161/JAHA.112.000075

Journal of the American Heart Association

These findings are in contrast with an earlier report of a rabbit study that multiple episodes (ie, >4) of angina in the 48 hours prior to the incidence of myocardial infarction resulted in a similar level of cardioprotection as that observed in patients who had experienced a single episode during that time period. This observation suggests that the myocardium does not become tolerant or insensitive to the effects of IPC when induced endogenously through multiple episodes of angina prior to prolonged coronary ischemia.

The present investigation demonstrates that 7 episodes of IPC, repeated daily, confer protection against IR-induced endothelial damage in the radial artery that is equal to that conferred by a single episode of IPC. Further, our results suggest that the protection provided by both single and repeated episodes of IPC are not mediated by a mechanism that involves COX-2, as the preadministration of the selective COX-2 inhibitor celecoxib did not alter the effect of IPC. However, as mentioned above, COX-2 has been shown to be an important mediator in the delayed IPC response. Several animal studies have demonstrated that cardioprotection afforded by delayed IPC is associated with an upregulation of the COX-2 protein 24 hours after IPC, along with an increased content of the by-products of COX-2 activity: prostaglandin E2, 6-keto-prostaglandin F1α. These prostaglandins are known to have independent protective effects in the setting of IR. This activity of COX-2 has been shown to be regulated by the inducible isoform of nitric oxide synthase, another critical signaling molecule in conventional preconditioning pathways. For these reasons, we anticipated that 7 daily episodes of IPC would put a COX-2-dependent signaling cascade into effect. However, our results suggest that the chronic preconditioning stimuli in this study may have provided endothelial protection through a pathway that differs from the conventional signaling pathways of acute preconditioning. This result is actually consistent with the results reported from Depre et al where the protection from repeated episodes of IPC were not dependent on nitric oxide synthase.

The fact that the present data were acquired in healthy volunteers and in forearm conduit vessels is acknowledged as a limitation. However, the model of forearm IR injury used in the present study has been previously shown to provide reliable and relevant information regarding the effect of various agents on the development of IR-induced endothelial dysfunction. The small sample size in the present study and our observed effect size for IR in the control groups, which was smaller than what we have reported previously, must also be acknowledged. However, we believe that the possibility of type I or II statistical errors is unlikely since the effect of IPC on FMD was more pronounced than what we had originally hypothesized, such that our statistical power remained high. However, the high variability in our blood flow data does not permit us to exclude the possibility of a type II error due to low statistical power.

The present study demonstrates, for the first time in humans, that repeated episodes of IPC confer significant and equipotent protection against IR-induced endothelial dysfunction in the forearm vasculature as that observed with a single episode of IPC. This chronic preconditioning regimen does not appear to be dependent on COX-2, which suggests that a novel

Figure 2. Change in the FMD response with IR (ΔFMD) in IR alone, 1-day IPC and 7-day IPC groups treated with placebo and celecoxib. n=10 per group. IR indicates ischemia-reperfusion; FMD, flow-mediated dilation; IPC, ischemic preconditioning.

In humans, only limited information is available concerning the effects of repeated preconditioning. To date, no human study has reported the impact of repeated, controlled IPC stimuli on the effect of IR. One prospective study, using self-reported episodes of angina as a surrogate for IPC, showed that multiple episodes (ie, >4) of angina in the 48 hours prior to the incidence of myocardial infarction resulted in a similar level of cardioprotection as that observed in patients who had experienced a single episode during that time period. This observation suggests that the myocardium does not become tolerant or insensitive to the effects of IPC when induced
signaling pathway, distinct from those known to be involved in acute preconditioning signaling, may be mediating the protective effects observed. With the inclusion of the current data, the evidence from human chronic preconditioning studies suggests that ischemia may be more effective than pharmacologic agents as a preconditioning trigger when applied in a prolonged fashion. The mechanistic differences between chronic IPC and chronic administration of agents such as nitroglycerin and HMG-CoA reductase inhibitors have yet to be determined and are an area of future research. Elucidating the mechanisms that govern chronic forms of preconditioning will permit a better understanding of the clinical potential for this new branch of preconditioning strategies.

Acknowledgments

The authors thank the staff of the John H. Daniels Cardiac Research Centre and the Mecklinger and Posluns Cardiac Catheterization Research Laboratory of the Mount Sinai Hospital, Toronto, Canada.

Sources of Funding

This work was supported by a grant-in-aid from the Heart and Stroke Foundation of Ontario. Dr. Parker holds a Career Investigator Award from the Heart and Stroke Foundation of Ontario, Canada.

Disclosures

None.

References

1. Ozize M, Baxter GF, Di Lisa F, Garcia-Dorado D, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R; Working Group of Cellular Biology of Heart of European Society of Cardiology. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2010;87:406–423.

2. Vinten-Johansen J, Zhao QZ, Nakamura M, Jordan JE, Ronson RS, Thourani VH, Guyton RA. Nitric oxide and the vascular endothelium in myocardial ischemia-reperfusion injury. Ann Y Acad Sci. 1999;874:354–370.

3. Laude K, Beauchamp P, Thulliez C, Richard V. Endothelial protective effects of preconditioning. Cardiovasc Res. 2002;55:466–473.

4. Kharbanda RK, Peters M, Walton B, Kattenhorn M, Mullen M, Klein N, Vallance P, Deanfield J, MacAllister R. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia–reperfusion in humans in vivo. Circulation. 2001;103:1624–1630.

5. Ehring T, Krajcar M, Baumgart D, Kompa S, Hummelgen M, Heusch G. Cholinergic and alpha-adrenergic coronary vasomotion [corrected] with increasing ischemia–reperfusion injury. Am J Physiol. 1995;268:H886–H894.

6. Scarabelli T, Stephanou A, Rayment N, Pasini E, Comini L, Curelo S, Ferrari R, Knight R, Latchman D. Atposis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. Circulation. 2001;104:253–256.

7. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cellular injury in ischemic myocardium. Circulation. 1986;74:1124–1136.

8. Liem DA, Honda HM, Zhang J, Woo D, Ping P. Past and present course of cardioprotection against ischemia-reperfusion injury. J Appl Physiol. 2007;103:2129–2136.

9. Leesar MA, Stoddard MF, Dawn B, Justi VG, Masden R, Bolli R. Delayed preconditioning mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation. 2001;103:2935–2941.

10. Walsh SR, Tang TY, Kullar P, Jenkins DP, Dutka DP, Gaunt ME. Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of periprocedural outcomes in randomised clinical trials. Eur J Cardiothorac Surg. 2008;34:985–994.

11. Bolter HE, Kharbanda R, Schmidt MR, Bottcher M, Kalkof AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rethling M, Sorensen HT, Redington AN, Nielsen TT. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375:727–734.

12. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation. 2005;111:742–746.

13. Gori T, Di Stollo G, Sicuro S, Dragoni S, Lisi M, Forconi S, Parker JD. Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight. Br J Clin Pharmacol. 2007;64:145–150.

14. Dragoni S, Gori T, Di SG, Sicuro S, Forconi S, Parker JD. Folic acid does not limit endothelial dysfunction induced by ischemia and reperfusion: a human study. J Cardiovasc Pharmacol. 2005;46:494–497.

15. Gori T, Dragoni S, Lisi M, Di Stollo G, Sonnino S, Fineschi M, Parker JD. Conduit artery constriction mediated by low flow a novel noninvasive method for the assessment of vascular function. J Am Coll Cardiol. 2008;51:1953–1958.

16. Yellon DM, Downey J. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113–1151.

17. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121–1135.

18. Lambiase PD, Edwards RJ, Cusack MR, Bucknall CA, Redwood SR, Marber MS. Exercise-induced ischemia initiates the second window of protection: evidence from human chronic preconditioning studies suggests that ischemia may be more effective than pharmacologic agents as a preconditioning trigger when applied in a prolonged fashion. The mechanistic differences between chronic IPC and chronic administration of agents such as nitroglycerin and HMG-CoA reductase inhibitors have yet to be determined and are an area of future research. Elucidating the mechanisms that govern chronic forms of preconditioning will permit a better understanding of the clinical potential for this new branch of preconditioning strategies.

19. Dana A, Baxter GF, Walker JM, Yellon DM. Prolonging the delayed phase of preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation. 2001;103:2935–2941.

20. Mannacio VA, Iorio D, De AV, Di LF, Musumeci F. Effect of rosuvastatin during sustained therapy: a human in vivo study. J Am Coll Cardiol. 2010;56:1291–1296.

21. Brugioni C, Colombo A, Airoldi F, Violante A, Focaccia A, Balestrieri P, Paolo EP, Golia B, Lepore S, Rizzi G, Scarpato P, Librera M, Bonizzi E, Ricciardelli B. Statin administration before percutaneous coronary intervention: effect on left ventricular mass in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004;110:674–678.

22. Mannocia VA, Iorio D, De AV, Li S, Musumeci F, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272–1278.

23. Pasceri V, Patti G, Ninusa A, Prisapino C, Richichi G, Di SG. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation. 2004;110:674–678.

24. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272–1278.

25. Mannocia VA, Iorio D, De AV, Li S, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg. 2008;136:1541–1548.

26. Liuni A, Luca MC, Gori T, Parker JD. Loss of the preconditioning effect of rosvastatin during sustained therapy: a human in vivo study. J Am Coll Cardiol. 2012;60:1503–1511.

27. Liuni A, Luca MC, Girardi D, Battifoggio E, De Angeli M, Neri M, D’Avino A, Gori T. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375:727–734.

28. Liuni A, Luca MC, Gori T, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation. 2005;111:742–746.

29. Shen Y-T, Depre C, Yan L, Park YJ, Tian B, Jain K, Chen L, Zhang Y, Kudej RK, Zhao X, Sadoshima J, Batres DE, Vatner SF. Repetitive ischemia by coronary stenosis induces a novel window of ischemic preconditioning. Circulation. 2008;118:1961–1969.

DOI: 10.1161/JAHA.112.000075
30. Depre C, Park JY, Shen YT, Zhao X, Qiu H, Yan L, Tian B, Vatner SF, Vatner DE. Molecular mechanisms mediating preconditioning following chronic ischemia differ from those in classical second window. *Am J Physiol Heart Circ Physiol*. 2010;299:H752–H762.

31. Cohen MV, Yang XM, Downey JM. Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning. *Circ Res*. 1994;74:998–1004.

32. Papadopoulos CE, Karvounis HI, Parharidis GE, Louridas GE. Multiple episodes of ischemic preconditioning are not associated with loss of benefit: preliminary clinical experience. *Can J Cardiol*. 2005;21:1291–1295.

33. Bolli R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. *Am J Physiol Heart Circ Physiol*. 2007;292:H19–H27.

34. Bolli R, Shimura K, Tang X-L, Kodani E, Xuan Y-T, Guo Y, Dawn B. Discovery of a new function of cyclooxygenase (Cox)-2: Cox-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. *Cardiovasc Res*. 2002;55:506–519.

35. Liuni A, Luca MC, Gori T, Parker JD. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. *J Am Coll Cardiol*. 2010;55:1002–1006.